MedTrace Logo

Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART

NCT03706950 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2018-10-18

No results posted yet for this study

Summary

This post-registration observational study is designed to monitor the safety parameters and efficacy of Elpida® in actual practice in the first-line treatment of HIV-1 infected patients on the background of the standard baseline ART.

Conditions

Interventions

DRUG

Elpida® + 2 NRTIs

Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy

Sponsors & Collaborators

  • Viriom

    lead INDUSTRY

Principal Investigators

  • Elena Yakubova, PhD · Viriom

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706950 on ClinicalTrials.gov